Pharvaris (NASDAQ:PHVS) Shares Gap Down – Here’s What Happened

Posted by James Quigley on Mar 19th, 2025

Pharvaris (NASDAQ:PHVS – Get Free Report) shares gapped down prior to trading on Monday . The stock had previously closed at $16.67, but opened at $16.23. Pharvaris shares last traded at $16.77, with a volume of 4,984 shares changing hands.

Analysts Set New Price Targets

Separately, JMP Securities lifted their price objective on Pharvaris from $46.00 to $55.00 and gave the company a “market outperform” rating in a report on Friday, January 31st.

View Our Latest Stock Report on Pharvaris

Pharvaris Trading Down 3.3 %

The stock has a fifty day simple moving average of $17.03 and a two-hundred day simple moving average of $19.11. The company has a market cap of $834.55 million, a PE ratio of -5.70 and a beta of -3.02.

Institutional Investors Weigh In On Pharvaris

Institutional investors have recently modified their holdings of the company. Public Employees Retirement System of Ohio purchased a new stake in shares of Pharvaris during the 3rd quarter worth approximately $57,000. JPMorgan Chase & Co. boosted its stake in shares of Pharvaris by 1,125.3% during the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company’s stock worth $59,000 after acquiring an additional 2,847 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Pharvaris during the 4th quarter worth approximately $64,000. Barclays PLC purchased a new stake in shares of Pharvaris during the 3rd quarter worth approximately $106,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Pharvaris during the 4th quarter worth approximately $111,000.

About Pharvaris

(Get Free Report)

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.